The present study demonstrated that empagliflozin could probably alleviate liver fibrosis during NASH via downregulation of NF-κB/SOX 9/OPN axis and upregulation of OCN in the hepatic tissues. The gene discussed is SPP1; the disease is metabolic dysfunction-associated steatohepatitis.